Abstract
This review article systematically and critically summarizes the current evidence regarding desipramine for treating children and adolescents with attention deficit hyperactivity disorder (ADHD).
PRISMA guideline was used for gathering the data. The databases of PubMed/Medline and Google scholar were electronically searched. This review included controlled clinical trials investigating the efficacy of desipramine for treating children and adolescents with ADHD.
The primary outcome measure was clinical improvement measured by valid and reliable objective instruments in order to assess the severity of ADHD clinical symptoms. Adverse effects were evaluated as well.
Out of 267 titles under the study, thirty three articles mentioned desipramine for treating ADHD. Two trials met the inclusion criteria. Desipramine decreases ADHD clinical symptoms. However, there are many concerns about its safety and efficacy.
In view of serious concerns about its safety and lack of enough well-controlled trials providing strong evidence about the efficacy of desipraimine, it should be prescribed for treating children with ADHD with a high precaution, and further well-controlled trials should be performed.
Keywords: Adolescents, antidepressive agents, attention deficit hyperactivity disorder, children, desipramine, therapeutics, tricyclic.
Current Drug Safety
Title:A Systematic Review of the Efficacy and Safety of Desipramine for Treating ADHD
Volume: 8 Issue: 3
Author(s): Ahmad Ghanizadeh
Affiliation:
Keywords: Adolescents, antidepressive agents, attention deficit hyperactivity disorder, children, desipramine, therapeutics, tricyclic.
Abstract: This review article systematically and critically summarizes the current evidence regarding desipramine for treating children and adolescents with attention deficit hyperactivity disorder (ADHD).
PRISMA guideline was used for gathering the data. The databases of PubMed/Medline and Google scholar were electronically searched. This review included controlled clinical trials investigating the efficacy of desipramine for treating children and adolescents with ADHD.
The primary outcome measure was clinical improvement measured by valid and reliable objective instruments in order to assess the severity of ADHD clinical symptoms. Adverse effects were evaluated as well.
Out of 267 titles under the study, thirty three articles mentioned desipramine for treating ADHD. Two trials met the inclusion criteria. Desipramine decreases ADHD clinical symptoms. However, there are many concerns about its safety and efficacy.
In view of serious concerns about its safety and lack of enough well-controlled trials providing strong evidence about the efficacy of desipraimine, it should be prescribed for treating children with ADHD with a high precaution, and further well-controlled trials should be performed.
Export Options
About this article
Cite this article as:
Ghanizadeh Ahmad, A Systematic Review of the Efficacy and Safety of Desipramine for Treating ADHD, Current Drug Safety 2013; 8 (3) . https://dx.doi.org/10.2174/15748863113089990029
DOI https://dx.doi.org/10.2174/15748863113089990029 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glycogen Synthase Kinase-3: A Potential Target for Drug Discovery in the Treatment of Neurodegenerative Disorders
Current Enzyme Inhibition Lithium, a Therapy for AD: Current Evidence from Clinical Trials of Neurodegenerative Disorders
Current Alzheimer Research Conference Report: 10th Clinical Trials on Alzheimer's Disease (CTAD), Boston MA, USA, November 1-4, 2017
CNS & Neurological Disorders - Drug Targets Global Child and Adolescent Mental Health Needs: Perspectives from a National Tertiary Referral Center in India
Adolescent Psychiatry Genetic Susceptibility to Prion Diseases in Humans and Mice
Current Genomics Progressive Supranuclear Palsy: Neuropsychopathological, Therapeutical and Bioethical Aspects
Current Alzheimer Research Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Second Generation Antipsychotics in Asperger’s Disorder and High Functioning Autism: A Systematic Review of the Literature and Effectiveness of Meta-Analysis.
Current Clinical Pharmacology GSK-3 Inhibitors: Discoveries and Developments
Current Medicinal Chemistry Hybrid PET Imaging in Neurologic Disease: PET/MRI Rather than PET/CT
Current Medical Imaging Transglutaminase-Catalyzed Crosslinking in Neurological Disease: From Experimental Evidence to Therapeutic Inhibition
CNS & Neurological Disorders - Drug Targets Genetic Features of MAPT, GRN, C9orf72 and CHCHD10 Gene Mutations in Chinese Patients with Frontotemporal Dementia
Current Alzheimer Research Applying Epigenetics to Alzheimer’s Disease via the Latent Early–life Associated Regulation (LEARn) Model
Current Alzheimer Research Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases
Current Pharmaceutical Design Encapsulation in Cell Therapy: Methodologies, Materials, and Clinical Applications
Current Pharmaceutical Biotechnology A Developmental Psychopathology Perspective of Obsessive-Compulsive Disorder
Current Psychiatry Research and Reviews Detection and Localization of Methionine Sulfoxide Residues of Specific Proteins in Brain Tissue
Protein & Peptide Letters Current Limitations in the Treatment of Parkinson’s and Alzheimer’s Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers
Current Medicinal Chemistry Update on Alzheimer’s Disease Therapeutics
Reviews on Recent Clinical Trials PET Radiotracers for Molecular Imaging in Dementia
Current Radiopharmaceuticals